Table 2. Grading of spleen amyloid and quantification of MZMs during amyloid development.
| Group | Treatment | Sacrificeday | No. ofmice | No. of mice withamyloid/amyloidgrade | No. micewith MZM | % decrease of MZM±SDin MZ with amyloid | % increase of MZM±SDin MZ without amyloid |
| B | AgNO3 | 4 | 11 | 0/0 | 11 | – | 9±25 |
| C | AgNO3 | 16 | 8 | 0/0 | 8 | – | 7±13 |
| D | AEF+AgNO3 | 1 | 4 | 0/0 | 4 | – | 66±34* |
| E | AEF+AgNO3 | 2 | 5 | 1/2+ | 1 | 24±24* | 26±54 |
| 4 | – | 16±10 | |||||
| F | AEF+AgNO3 | 4 | 18 | 1/0 | 1 | – | 18±35 |
| 8/1+ | 8 | ND | 35±23** | ||||
| 3/2+ | 3 | 53±9*** | 49±24* | ||||
| 5/3+ | 5 | 61±6** | # | ||||
| 1/4+ | 0 | 100*** | # | ||||
| G | AEF+AgNO3 | 16 | 13 | 2/3+ | 2 | 80±8*** | # |
| 6/4+ | 6 | 92±10*** | # | ||||
| 5/4+ | 0 | 100*** | # |
See figure 1 for definition of groups. *p<0.05; ** p≤0.01; *** p≤0.001.
Presence of antibodies specific for ER-TR9.
ND = not determined, MZ = marginal zone and # = no marginal zones without amyloid.